Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Abstract Background Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Stu...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing, Yung-Jue Bang
Format: Artykuł
Język:English
Wydane: BMC 2018-03-01
Seria:BMC Cancer
Hasła przedmiotowe:
Herceptin
Trastuzumab
Breast cancer
Gastric cancer
HER2-positive
Dostęp online:http://link.springer.com/article/10.1186/s12885-018-4183-2

Internet

http://link.springer.com/article/10.1186/s12885-018-4183-2

Podobne zapisy